Healthcare [ 7/13 ] | Biotechnology [ 82/163 ]
NASDAQ | Common Stock
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States.
The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.
It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases.
The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021.
Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 13, 24 | -10.19 Decreased by -1.10 K% | -1.18 Decreased by -763.37% |
| Mar 28, 24 | -116.21 Decreased by -11.07 K% | -4.80 Decreased by -2.32 K% |
| Nov 9, 23 | -0.11 Decreased by -132.35% | -1.10 Increased by +90.00% |
| Aug 3, 23 | -0.59 Increased by +57.25% | -0.80 Increased by +26.25% |
| May 4, 23 | -0.85 Increased by +64.58% | -0.97 Increased by +12.37% |
| Mar 29, 23 | -1.04 Increased by +45.83% | -0.73 Decreased by -42.47% |
| Nov 7, 22 | 0.34 Increased by +116.67% | -1.09 Increased by +131.19% |
| Aug 4, 22 | -1.38 Increased by +36.11% | -1.77 Increased by +22.03% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 23 | 571.00 K Decreased by -36.27% | -8.17 M Increased by +16.76% | Decreased by -1.43 K% Decreased by -30.63% |
| Sep 30, 23 | 236.00 K Decreased by -98.42% | -5.23 M Decreased by -263.78% | Decreased by -2.22 K% Decreased by -10.47 K% |
| Jun 30, 23 | 643.00 K Decreased by -37.75% | -8.19 M Increased by +36.91% | Decreased by -1.27 K% Decreased by -1.35% |
| Mar 31, 23 | 475.00 K Decreased by -59.51% | -9.96 M Increased by +54.85% | Decreased by -2.10 K% Decreased by -11.49% |
| Dec 31, 22 | 896.00 K Increased by +309.13% | -9.81 M Increased by +48.89% | Decreased by -1.10 K% Increased by +87.51% |
| Sep 30, 22 | 14.95 M Increased by +1.01 K% | 3.19 M Increased by +118.35% | Increased by +21.35% Increased by +101.66% |
| Jun 30, 22 | 1.03 M Decreased by -69.21% | -12.99 M Increased by +24.07% | Decreased by -1.26 K% Decreased by -146.59% |
| Mar 31, 22 | 1.17 M Increased by +147.99% | -22.05 M Increased by +28.13% | Decreased by -1.88 K% Increased by +71.02% |